Executive equity grant at Adaptive Biotechnologies (NASDAQ: ADPT)

Rhea-AI Filing Summary

RUBINSTEIN JULIE reported acquisition or exercise transactions in this Form 4 filing.

Adaptive Biotechnologies Corp reported that President and COO Julie Rubinstein received a grant of 81,250 shares of Common Stock on March 4, 2026. The award was recorded at a price of $0.0000 per share, indicating it was granted for no cash consideration. Following this equity grant, Rubinstein’s directly owned holdings increased to 656,485 shares of Common Stock, reflecting a larger personal stake in the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBINSTEIN JULIE

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		81,250	A	$0	656,485	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADPT officer Julie Rubinstein report?

Julie Rubinstein reported receiving a grant of 81,250 shares of Adaptive Biotechnologies Common Stock. The shares were awarded at a stated price of $0.0000 per share, increasing her directly owned stake to 656,485 shares after the transaction was recorded.

How many ADPT shares does Julie Rubinstein own after this Form 4?

After the reported equity grant, Julie Rubinstein directly owns 656,485 shares of Adaptive Biotechnologies Common Stock. This total reflects the addition of 81,250 shares granted on March 4, 2026, as disclosed in the Form 4 insider transaction report.

Was cash paid for the 81,250 ADPT shares granted to Julie Rubinstein?

No cash was paid for the 81,250 shares granted to Julie Rubinstein, as they were recorded at a transaction price of $0.0000 per share. This indicates a stock-based award rather than an open-market purchase of Adaptive Biotechnologies shares.

What does transaction code "A" mean in Julie Rubinstein’s ADPT Form 4?

The transaction code “A” in Julie Rubinstein’s Form 4 indicates a grant, award, or other acquisition of shares. In this case, she acquired 81,250 shares of Adaptive Biotechnologies Common Stock as an equity award, increasing her direct ownership position.

Is Julie Rubinstein’s ADPT share ownership direct or indirect in this filing?

The Form 4 shows Julie Rubinstein’s ownership as direct, marked with ownership code “D”. The 81,250 shares of Common Stock granted on March 4, 2026 are held directly, contributing to her total direct holdings of 656,485 Adaptive Biotechnologies shares.